key: cord-0770218-si1lbz73
authors: Calderón‐Parra, Jorge; Mills‐Sanchez, Patricia; Moreno‐Torres, Victor; Tejado‐Bravo, Sandra; Romero‐Sánchez, Isabel; Balandin‐Moreno, Bárbara; Calvo‐Salvador, Marina; Portero‐Azorín, Francisca; García‐Masedo, Sarela; Muñez‐Rubio, Elena; Ramos‐Martinez, Antonio; Fernández‐Cruz, Ana
title: COVID‐19‐associated pulmonary aspergillosis (CAPA): Risk factors and development of a predictive score for critically ill COVID‐19 patients
date: 2022-03-15
journal: Mycoses
DOI: 10.1111/myc.13434
sha: 975bdd8cb5f80855d33b4a93335f2b52ddc58176
doc_id: 770218
cord_uid: si1lbz73

BACKGROUND: COVID‐19‐associated pulmonary aspergillosis (CAPA) is a major complication of critically ill COVID‐19 patients, with a high mortality rate and potentially preventable. Thus, identifying patients at high risk of CAPA would be of great interest. We intended to develop a clinical prediction score capable of stratifying patients according to the risk for CAPA at ICU admission. METHODS: Single centre retrospective case–control study. A case was defined as a patient diagnosed with CAPA according to 2020 ECMM/ISHAM consensus criteria. 2 controls were selected for each case among critically ill COVID‐19 patients. RESULTS: 28 CAPA patients and 56‐matched controls were included. Factors associated with CAPA included old age (68 years vs. 62, p = .033), active smoking (17.9% vs. 1.8%, p = .014), chronic respiratory diseases (48.1% vs. 26.3%, p = .043), chronic renal failure (25.0% vs. 3.6%, p = .005), chronic corticosteroid treatment (28.6% vs. 1.8%, p < .001), tocilizumab therapy (92.9% vs. 66.1%, p = .008) and high APACHE II at ICU admission (median 13 vs. 10 points, p = .026). A score was created including these variables, which showed an area under the receiver operator curve of 0.854 (95% CI 0.77‐0.92). A punctuation below 6 had a negative predictive value of 99.6%. A punctuation of 10 or higher had a positive predictive value of 27.9%. CONCLUSION: We present a clinical prediction score that allowed to stratify critically ill COVID‐19 patients according to the risk for developing CAPA. This CAPA score would allow to target preventive measures. Further evaluation of the score, as well as the utility of these targeted preventive measures, is needed.

The coronavirus disease pandemic has affected more than 250 million people, with more than 5 million deaths due to this condition. 1 One third of hospitalised patients with COVID-19 will develop severe acute respiratory distress syndrome (ARDS), which usually leads to intensive care unit (ICU) admission and mechanical ventilation. 2 COVID-19-associated pulmonary aspergillosis (CAPA) has recently been recognised as a major complication of critically ill COVID-19 patients. 3 It is estimated that 10%-20% of ICU-admitted COVID-19 patients eventually develop CAPA. 4, 5 Recent studies have shown that cumulative incidence may vary from 5% or less to rates close to 40%, with higher incidence in patients needing mechanical ventilation. 6 Additionally, this entity is a life-threatening condition, with mortality rates usually exceeding 60% despite appropriate antifungal treatment. 5, 7 Accordingly, some authors have proposed the use of antifungal prophylaxis 8, 9 or the implantation of screening protocols along with pre-emptive treatment when Aspergillus spp. is isolated from respiratory samples. 10 Applying these special measures to all critically ill COVID-19 patients, including patients at low risk for CAPA, could result in patient's harm due to secondary effects of inappropriate antifungal therapy 11, 12 and lack of efficiency. Thus, identifying patients at high risk of CAPA in order to target the aforementioned measures would be of great interest. However, to date, studies that attempted to identify risk factors for CAPA development are scarce and show contradictory results. 4, 13, 14 Furthermore, none of these studies has resulted in a score capable to predict CAPA development at ICU admission.

We intend to identify factors associated with the occurrence of CAPA among critically ill COVID-19 patients and to develop a clinical score capable of stratifying them according to the risk for CAPA at ICU admission.

We performed a single centre retrospective case-control study. Our hospital is a 613-bed tertiary teaching hospital in Madrid, with a catchment area of 550.000 inhabitants, with 22 ICU beds, that increased to 64 ICU beds during the first waves of the COVID-19 pandemic.

Cases were identified from a prospective cohort that includes all patients diagnosed with invasive fungal infection at our centre since January 2018. A case was defined as a patient diagnosed with CAPA between March 2020 and August 2021, which corresponded to the first 5 waves in our setting. CAPA was defined according to 2020 ECMM/ISHAM criteria. 15 Cases were classified either as possible, probable or proven CAPA.

Controls were selected from a prospective cohort including all ICU-admitted patients with ARDS due to COVID-19. Controls were matched to cases by admission date. 2 controls were selected for each case. As one of our main objectives was to identify risk factors for CAPA development, which could include patient's age, sex, comorbidities and COVID-19 severity, we decided not to match controls according to these variables. Data were collected from electronic medical records and managed using REDCap electronic capture tools, 16 with a license provided to Puerta de Hierro-Segovia de Arana Research Institute (IDISPHSA for its Spanish abbreviation). 17 Data collected using REDCap platform were anonymised and included demographics, comorbidities, microbiological data and outcomes.

The study was approved by the hospital ethics committee (protocol identification PI-10/22, reference 07/117290.9/22). Since this was a retrospective, non-interventional study and only required collection of previously generated and anonymised data, informed consent was not required.

Galactomannan (GM) qualitative detection was performed by sandwich chemiluminescent immunoassay (CLIA) Aspergillus Galactomannan Ag VIRCLIA@ monotest (Vircell, Granada, Spain).

According to manufacter's instructions, a result equal or greater than 0.20 was considered positive, both in serum and in bronchoalveolar lavage. This cut-off point has been validated against the wellestablished indexes of GM Platelia, BioRad. 18 Respiratory samples for fungal cultures were grown in Sabouraudgentamicin-chloramphenicol agar and antifungal susceptibility tests were performed by broth microdilution at the national reference centre (Carlos III Health Institute, National Microbiology Centre, Majadahonda, Spain). In some samples, direct visualisation by KOH stain was performed at the request of the attending physician.

All tests were performed according to manufacturer´s instructions.

No CAPA screening protocol was implemented during the study period and the tests were ordered at the discretion of the attending physician. Fibrobronchoscopy and bronchoalveolar lavage were performed under specific request of attending physician.

ARDS was defined according to Berlin's criteria. 19 The acute physiology and chronic health evaluation (APACHE II score 20 

Our primary objective was to identify risk factors for CAPA among critically ill COVID-19 patients. Our secondary objective was to develop and validate a clinical prediction score for the occurrence of CAPA among critically ill COVID-19 patients based on data available at ICU admission. We also sought to describe characteristics of CAPA patients and factors associated with poor outcome.

Data are presented as median and interquartile range (IQR) for quantitative variables, and as absolute and percentage value for qualitative variables. For the primary and secondary purposes, inferential statistical analysis was done using chi-square test and Fisher exact test (when necessary) for qualitative variables and Mann-Whitney's U for quantitative ones. A 180-day mortality analysis was performed by means of Cox regression and Kaplan-Meier curves. Hazard ratios (HR) with 95% confidence intervals (CI) are provided.

To create the score, variables clinically and statistically significant in the previous univariate analysis were included in a multivariate logistic regression model in order to estimate each patient's predicted probability of developing CAPA. 21, 22 As we did not intend to seek for independent-associated factors, we did not establish a limit of covariate based on the number of cases. [22] [23] [24] [25] If the variables included in showed to improve the predictive model, they were considered for the final predicted probability calculation. Afterwards, the predicted probability was transformed into a punctuation score based on the beta-coefficient from this model. The score was subsequently applied to all patients. Calibration of the score was tested by the Hosmer-Lemeshow goodness-to-fit test. 25 Discrimination of the score was measured by the area under the receiving operator curve (AUC-ROC) with the 95% CI. A bootstrap procedure was employed for internal validation. The score was applied to 1000 bootstrap samples, and the optimism was calculated. Then, the bootstrapped corrected AUC-ROC was computed. A value of AUC-ROC of 0.5 indicates random predictions, and a value of 1 indicates perfect discrimination. A model with an AUC-ROC roughly above 0.7 is considered to be useful to perform predictions of individual subjects. 25 Cut-off points along with sensitivity, specificity and likelihood ratios are provided. Negative and positive predictive values were calculated applying the score to a population with a prevalence similar to that of our ICU cohort.

Bilateral p values below .05 were considered statistically significant. All statistical analyses were performed using SPSS version 25 software (SPSS Inc, IBM, Chicago, Illinois, United States).

Between March 2020 and August 2021, 28 CAPA patients were prospectively identified in our centre, including 22 ICU-admitted patients, representing 6.04% (22/364) patients admitted to ICU with severe ARDS due to COVID-19. In addition to the 22 that were at the ICU ward, 3 others were on non-invasive mechanical ventilation at an intensive respiratory care unit and the remaining 3 were severe ARDS COVID-19 cases receiving the highest possible oxygen supplementation at conventional hospitalisation. Of note, all of the 6 patients not admitted to ICU had developed critical COVID-19 with severe ARDS and had criteria for ICU admission. Therefore, they fulfilled ECMM/ISHAM 2020 consensus criteria for CAPA. However, due to healthcare system overload (and in particular the lack of available ICU beds), as well as age and basal comorbidity of some patients, other patients with potentially better survival opportunities were prioritised over them for ICU admission. Six (21.4%) CAPA patients were diagnosed during the first, 6 (21.4%) during the second wave, 5 (17.9%) during the third, 6 (21.4%) during the fourth wave and 5 (17.9%) during the fifth wave. Accordingly, 56-matched controls were selected.

Characteristics of the 28 CAPA patients included in the study are shown in Table 1 .

Median time from hospital admission to CAPA diagnosis was 21 days (IQR 11-41), and median time from ICU admission to CAPA was 11 days (IQR 6-42).

Sixteen patients (57.1%) were classified as probable CAPA and 12 (42.8%) as possible CAPA. Comparison between probable and possible cases is shown in Table S1 . Bronchoalveolar lavage culture was only available in 2 out of 12 possible CAPA and none of them had GM performed in this sample. There were no cases of proven CAPA. 

When comparing patients with and without CAPA regarding baseline characteristics ( Note: All 7 variables included in the regression model improved the predictive model, so all of them were considered to calculate the score punctuation. In order to calculate the score punctuation, beta-coefficients of categorical variables were transformed into points using the following rule: beta-coefficient lower than 0.5:2 points; beta-coefficient 0.5-1.5:3 points; beta-coefficient 1.6-4:4 points; beta-coefficient greater than 4:5 points. In the case of non-categorical variables (age and APACHE II), punctuation was divided in 3 groups, the first with no punctuation: a second group with a low punctuation and a third with high punctuation. Due to higher beta-coefficient for age compared to APACHE II, age was given more weight to the score. Hence, when applying this score to critically ill COVID-19 patients in our population, we would be able to identify 3 groups of patients according to CAPA risk: 1-Very low risk for CAPA: patients with a score inferior to 6 (predicted risk lower to 0.5%); 2-Intermediate risk for CAPA: patients with a score between 6 and 9

(predicted risk 5%-10%); 3-High risk for CAPA: patients with a score equal or greater than 10 (predicted risk greater than 25%). However, if the same score is applied in other population with a high prevalence of CAPA (ie, 15%), we would identify 2 groups of patients:

1-Very low risk for CAPA: patients with score inferior to 6 (predicted risk lower than 1%); 2-High risk for CAPA: patients with score equal or greater than 6 (predicted risk greater than 30%). Based on the aforementioned risk factors, we constructed a clinical prediction score, the CAPA score that reliably stratified critically ill COVID-19 patients according to their risk for CAPA development.

To the best of our knowledge, this is the first published score effective to predict CAPA risk. In our population, a patient with a CAPA 

Factors associated with inhospital mortality among patients with COVID-associated pulmonary aspergillosis score below 6 points would have a risk for CAPA inferior to 0.5%.

Additionally, a patient with a CAPA score value equal or greater than 10 would present a CAPA risk over 25%.

Although the prevalence of CAPA in our ICU-admitted patients (6.04%) is similar to other works 27 and is consistent with studies in our setting 31 and autopsy studies, 32 some other authors have noted a higher prevalence, 4, 12, 28, 33 up to 30%. 34 These differences could be related to regional variations in incidence. 35 Using the same cut-off of 6 points in a high prevalence population to identify patients at low risk would remain adequate, as it would identify patients with a risk of developing CAPA of approximately 1%. Of note, in populations with a higher prevalence of CAPA, the cut-off of 6 points would be enough to identify patients at high risk, since patients with 6 or more points would present a risk greater than 40%.

Some studies suggest the efficacy of antifungal prophylaxis in preventing CAPA, 8, 9 while other authors consider systematic screening in all patients. 10 However, all those studies have failed to demonstrate a benefit of these measures, in terms of survival,

Kaplan-Meier survival curves of 180-day mortality among different population of COVID-associated pulmonary aspergillosis (CAPA) and controls. Survival analysis was made by means of Cox regression. Hazards ratios (HR) with their 95% confidence interval (CI) are presented. Figure 1A represents survival curve among patients with CAPA and ICU controls. Adjusted HR (aHR) was obtained after adjusting for age, smoking, chronic respiratory disease, immunocompromised status, prior chronic corticoid treatment, chronic renal failure, renal replacement therapy, APACHE II at ICU admission and blood component transfusion. Figure 1B represents survival curve according to 2020 ECMM/ISHAM consensus criteria CAPA classification and Figure 1C Ours is a single centre retrospective study and has the inherent limitations of this design. One of the major limitations of our study is the relative small sample size, which may have limited the power of the statistical analysis. Another limitation is that there was no CAPA screening protocol in our institution, and, consequently, a respiratory fungal culture was not available for every control patient, so it is not possible to exclude that a small proportion of the controls could actually have CAPA. However, the prevalence of CAPA in our institution is similar to that found in similar settings 31 as well as in recent systematic reviews, 5 In conclusion, we have developed and internally validated a clinical prediction score that allowed to stratify critically ill COVID-19 patients according to the risk for developing CAPA. Accordingly, at ICU admission, patients could be classified as low risk (score inferior to 6), intermediate risk (score between 6 and 9) and high risk (score equal or greater than 10). This CAPA score would enable targeting preventive measures such as periodic screening or antifungal prophylaxis to patients at high risk who could benefit most from them, while avoiding these measures in patients at low risk. Further evaluation of the score, as well as the usefulness of preventive measures in patients at high risk, is warranted. 

Supervision (lead)

Validation (lead)

Writing -original draft (lead)

Writing -review & editing (lead). Patricia Mills-Sanchez: Conceptualization (equal)

Data curation (equal)

Investigation (equal)

Conceptualization (equal)

Data curation (equal); Formal analysis (equal)

Investigation (equal)

Writing -review & editing (equal)

Isabel Sánchez-Romero: Methodology (equal); Writing -review & editing (equal)

Marina Calvo-Salvador: Writing -review & editing (equal)

Sarela García-Masedo: Methodology (equal)

Elena Muñez Rubio: Writing -review & editing (equal)

Supervision (equal)

Validation (equal)

Writing -review & editing (equal)

An interactive web-based dashboard to track COVID-19 in real time

Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry

Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis

Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology

Incidence and mortality of COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis

COVID-19-associated pulmonary aspergillosis

COVID-Associated pulmonary aspergillosis and its related outcomes: a single-center prospective observational study

Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study

Inhaled liposomal amphotericin-B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis/aspergillus tracheobronchitis

Systematic screening for COVID-19 associated invasive aspergillosis in ICU patients by culture and PCR on tracheal aspirate

Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns

A review of significance of Aspergillus detection in airways of ICU COVID-19 patients

Risk factors for invasive Aspergillosis in patients admitted to the intensive care unit with Coronavirus Disease 2019: a multicenter retrospective study

COVID-19 associated pulmonary aspergillosis

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ ISHAM consensus criteria for research and clinical guidance

Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support

The REDCap consortium: building an international community of software platform partners

Comparison of the performance of two galactomannan detection tests

Acute respiratory distress syndrome: the Berlin definition

APACHE II: a severity of disease classification system

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

Statistical primer: propensity score matching and its alternatives †

Relaxing the rule of ten events per variable in logistic and Cox regression

No rationale for 1 variable per 10 events criterion for binary logistic regression analysis

Applied Logistic Regression, 2nd edn

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study

Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort

Incidence and risk factors of COVID-19-associated pulmonary Aspergillosis in intensive care unit-A monocentric retrospective observational study

COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan

Aspergillus in critically Ill COVID-19 patients: a scoping review

Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity

Invasive mould disease in fatal COVID-19: a systematic review of autopsies

Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: results from the prospective AspCOVID-19 study

Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review

COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges

COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it?

Association of COVID-19-associated pulmonary Aspergillosis with cytomegalovirus replication: a case-control study

Aspergillus test profiles and mortality in critically Ill COVID-19 patients

Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA)